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Clinical renoprotection trials involving angiotensin II-receptor placebo over a period of three years [6]. The study found
antagonists and angiotensin-converting-enzyme inhibitors. The that the risk for the combined end-point of doubling of
leading cause of end-stage renal disease (ESRD) is diabetic the baseline serum creatinine level or the need for dialysisnephropathy. Interventions that prevent or palliate renal dis-
was reduced 53% for those patients receiving an ACEease have a positive impact by improving patient care and
inhibitor. However, risk reduction was not adjusted todiminishing healthcare costs. The following review summarizes
clinical trals that evaluated treatment in various patient popula- account for the benefit due to the additional blood-pres-
tions including Type 2 diabetic patients with microalbuminuria, sure reduction in those patients receiving ACE-inhibitor
subjects with proteinuric non-diabetic nephropathies, and Type treatment. In the Ramipril Efficacy In Nephropathy1 and Type 2 diabetic patients with overt nephropathy. These
(REIN) Study, 352 patients with non-diabetic CRI ran-clinical trials have demonstrated that agents directly affecting
the renin-angiotensin-aldosterone system provide renal protec- domly assigned to receive either ACE inhibitor or pla-
tion beyond that attributable to blood pressure control. cebo achieved similar blood-pressure control. Patients
with 3 g/day proteinuria at baseline and randomized
to ACE inhibitor, achieved a significant stabilization of
The leading cause of end-stage renal disease (ESRD) glomerular filtration rate (GFR) that led to an early termi-
in Europe, the United States, and Japan today is diabetic nation of placebo treatment in these patients [7]. An
nephropathy [1]. Interventions that prevent or palliate amended protocol to the study allowed these patients
renal disease will have a positive impact by improving with 3 g/day proteinuria to receive study drug rather
patient care and diminishing healthcare costs. In the early than placebo. In addition, those patients who were ran-
1980s, before renoprotective agents were available, death domized to the ACE inhibitor group continued therapy.
in diabetic patients would occur within five to ten years Patients who were switched from placebo to ACE inhibi-
following the onset of persistent proteinuria [2–4]. The tor showed a significant reduction in the rate of decline
two main treatment strategies for primary prevention of of renal failure. Patients continuing on ACE inhibitor
diabetic nephropathy are improvement in glycemic con- treatment showed a further reduction in the rate of de-
trol and blood pressure lowering, especially with agents cline of GFR, similar to that associated with the normal
that directly affect the renin-angiotensin-aldosterone aging process. Patients who received ACE inhibitor from
system (RAAS). the start of the REIN Study had a significantly lower
risk of reaching ESRD compared with those who were
switched to ACE inhibition after the initial phase of theANGIOTENSIN CONVERTING ENZYME
study. In addition, these patients in the former groupINHIBITORS AS RENOPROTECTIVE AGENTS
did not progress to ESRD during the 36 to 54 month-Data indicate that angiotensin-converting-enzyme
follow-up period [8]. A small number of patients who(ACE) inhibitors are renoprotective in Type 1 diabetics
continued on ACE inhibitor therapy experienced an in-with nephropathy [5]. ACE inhibitors also have proven
crease in GFR after prolonged treatment [9]. Those pa-effective in non-diabetic patients with chronic renal dis-
tients enrolled in the REIN Study with proteinuria lessease. Patients with chronic renal insufficiency (CRI; N 
than 3 g/day (N  186) were followed for a median of583) were randomized to receive either benazapril or
31 months following randomization. In this group of
patients, ACE inhibitor treatment significantly reduced
the incidence of ESRD [10].Key words: angiotensin II-receptor antagonists, ACE inhibitors, ESRD,
renoprotection. Specific kidney protection by ACE inhibitors com-
pared with various other antihypertensive treatment reg- 2003 by the International Society of Nephrology
S-77
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Table 1. Effects of ACE inhibitors on proteinuria and progression of renal disease in Type 2 diabetes
Renal assessment for subjects receiving ACE inhibitor
Treatment
Study N (ACE-I vs.) Proteinuria Renal function ESRD
Walker et al. J Am Soc Nephrol 3:339, 1992 134 Diuretic No improvement No additional stabilization Not determined
Ravid et al. Ann Intern Med 118:577, 1993 94 Placebo Improvement Stabilized Not determined
Lebovitz et al. Kidney Int 45 (Suppl 45):S150, 1994 121 CT Improvement Stabilized
(baseline UA 300 mg/d) Not determinedNo additional stabilization
(baseline UA 300 mg/d)
Bakris et al. Kidney Int 50:1641, 1996 18 CCB No improvement No additional stabilization Not determined
16 -blocker Improvement Stabilized
Ahmad et al. Diabetes Care 20:1576, 1997 103 Placebo Improvement No additional stabilization Not determined
Nielsen et al. Diabetes 46:1182, 1997 43 -blocker Improvement No additional stabilization Not determined
The UKPDS Study Group, BMJ 317:703, 1998 758 -blocker No improvement No additional stabilization Not determined
Fogari et al. J Hum Hypertens 13:47, 1999 107 CCB Improvement No additional stabilization Not determined
Estacio et al. N Engl J Med 338:645 (ABCD), 1998 470 CCB No improvement No additional stabilization Not determined
Ruggenenti et al. Am J Kidney Dis 35:1155, 2000 (REIN) 27 CT Not determined No additional stabilization No improvement(worsening renal function)
HOPE Study Investigators, Lancet 355:253, 2000 3577 Placebo Improvement Not determined No improvement
CT is conventional therapy.
imens has not been demonstrated consistently in patients ANGIOTENSIN II RECEPTOR ANTAGONISTS
AS RENOPROTECTIVE AGENTSwith Type 2 diabetes. As shown in Table 1, reduction of
proteinuria with corresponding stabilized renal function Several studies have shown that ACE inhibitors and
was observed in three studies [Ravid et al (1993), Lebo- angiotensin II receptor blockers (ARB) slow the pro-
vitz et al (1994), Bakris et al (1996), ACEI vs. -blocker]. gression of normoalbuminuria to microalbuminuria and
In other studies, reduction of proteinuria was not associ- microalbuminuria to overt nephropathy [11–16]. The most
ated with stabilized renal function [Ahmad et al (1997), recent trials evaluating the effects of ARBs on this pro-
Nielson et al (1997), Fogari et al (1999)]. Three studies, gression of proteinuria include the Irbesartan in Hyper-
tensive, Microalbuminuric, Type 2 Diabetic Patients Trialincluding UKPDS and ABCD, did not show improve-
(IRMA 2) [17] and Microalbuminuria Reduction with Val-ment in either proteinuria or stabilization of renal func-
sartan (MARVAL) Trial [18]. Results from each trial aretion [UKPDS Study Group (1998), Estacio et al (1998),
consistent with results from previous studies using ACEBakris et al (1996), ACE inhibitor vs. calcium channel
inhibitors [11, 12], other ARBs [13, 14], or a combinationantagonist]. Furthermore, most of these studies did not
of each class of these pharmacological agents [15, 16].evaluate the affect of ACE inhibitor therapy on the pro-
In IRMA2, 590 hypertensive, Type 2 diabetic subjectsgression to ESRD. Of the two studies that did, neither
with persistent microalbuminuria (20 to 200 g/min) andshowed that ACE inhibitors prevented or slowed the pro-
serum creatinine 1.5 mg/dL in men and 1.1 mg/dLgression to ESRD [Ruggenenti, et al (2000), HOPE Study
in women were randomized to receive placebo, irbesartanInvestigators (2000)]. In the Microalbuminuria, Cardio-
150 mg qd, or irbesartan, 300 mg qd over a two-yearvascular, and Renal Outcomes – Heart Outcomes Pre-
period. Dose adjustments were made at two-week inter-vention Evaluation (MICRO-HOPE) substudy (HOPE
vals to achieve a blood-pressure goal of 135/85
Study Investigators, 2000), ramipril decreased the pro-
mm Hg. Thirty patients in the placebo group developed
gression of microalbuminuria to overt nephropathy but overt nephropathy compared with 10 patients in the irbe-
failed to show a benefit in reducing the occurrence of sartan-300-mg group (P  0.001). Nineteen patients de-
ESRD. Similarly, evaluation of a large cohort of subjects veloped overt nephropathy in the irbesartan 150 mg
with proteinuric non-diabetic nephropathies (N  352) group, but this was not statistically significant. The de-
followed prospectively for three years in the Ramipril cline in creatinine clearance during the initial three
Efficacy in Nephropathy (REIN) study [Ruggenenti, et months of follow-up was 0.9, 1.0, and 1.9 mL/min/1.73
al (2000)], showed stabilization of glomerular filtration m2 in the placebo, 150-mg, and 300-mg irbesartan arms,
rate (GFR) but no benefit on ESRD. The authors con- respectively. The decline in the 3 to 24 month follow-up
cluded that “the use of ACE inhibitors to prevent renal period was 0.1, 0.2, and 0.2 mL/min/1.73 m2 in the pla-
disease progression in patients with Type 2 diabetes should cebo, 150 mg, and 300 mg arms, respectively. The restora-
be considered premature, at least until results of ad hoc, tion to normoalbuminuria by the last visit was 34% in
prospective, randomized trials are available.” Such trials the irbesartan 300-mg group (P  0.006), 24% in the
using ARBs have recently been reported and are consid- irbesartan 150-mg group, and 21% in the placebo group.
In the MARVAL Trial, 322 Type 2 diabetic subjectsered in the next section.
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Table 2. Baseline characteristics
RENAAL IDNT
Losartan Placebo Irbesartan Amlodipine Placebo
(N  751) (N  762) (N  579) (N  567) (N  569)
Age years 607 607 59.37.1 59.17.9 58.38.2
Male 462 (61.5) 494 (64.8) 378 (65) 359 (63) 403 (71)
Female 289 (38.5) 268 (35.2) 201 (35) 208 (37) 166 (29)
Race
Asian 117 (15.6) 135 (17.7) 24 (4)a 34 (6)a 27 (5)a
Black 125 (16.6) 105 (13.8) 63 (11) 87 (15) 78 (14)
Caucasian 358 (47.7) 378 (49.6) 438 (76) 389 (69) 415 (73)
Hispanic 140 (18.6) 136 (17.8) 28 (5) 29 (5) 26 (5)
Other 11 (1.5) 8 (1.0) 26 (4) 28 (5) 23 (4)
Medical history
Body mass indexb 306 296 31.05.6 30.95.9 30.55.9
Blood pressure mm Hg
Systolic 15219 15320 16020 15919 15820
Diastolic 8210 8211 8711 8711 8711
Mean arterialc 105.510.9 106.011.6 Not reported Not reported Not reported
Pulsed 69.417.4 70.818.1 Not reported Not reported Not reported
Use of antihypertensive agents 693 (92.3) 721 (94.6) Not reported Not reported Not reported
Angina pectoris 65 (8.7) 75 (9.8) Not reported Not reported Not reported
Myocardial infarction 75 (10.0) 94 (12.3) Not reported Not reported Not reported
Coronary revascularization 1 (0.1) 1 (0.1) Not reported Not reported Not reported
Stroke 0 1 (0.1) Not reported Not reported Not reported
Lipid disorders 234 (31.2) 271 (35.6) Not reported Not reported Not reported
History of cardiovascular disease Not reported Not reported 158 (27) 171 (30) 164 (29)
Amputations 65 (8.7) 69 (9.1) Not reported Not reported Not reported
Neuropathy 375 (49.9) 379 (49.7) Not reported Not reported Not reported
Retinopathy 494 (65.8) 470 (61.7) 401 (69) 362 (64) 380 (67)
Smoking (current) 147 (19.6) 130 (17.1) Not reported Not reported Not reported
Laboratory
Urine albumin:creatininee median, mg/g 1237 1261
Serum creatininef mg/dL 1.90.5 1.90.5 1.675.3 1.650.61 1.690.57
Urinary protein excretion g/24 h
Median Not reported Not reported 1.9 1.9 1.9
Interquartile range Not reported Not reported 1.6–5.4 1.6–5.2 1.8–5.2
Serum cholesterol mg/dL
Total 22756 22955 Not reported Not reported Not reported
LDL 14247 14245 Not reported Not reported Not reported
HDL 4516 4515 Not reported Not reported Not reported
Serum triglyceridesg mg/dL 213180 225200 Not reported Not reported Not reported
Hemoglobinh g/dL 12.51.9 12.51.8 Not reported Not reported Not reported
Hemoglobin A1c % 8.51.7 8.41.6 8.11.7 8.21.7 8.21.7
Data presented are N (%); plus/minus values are mean  standard deviation. Differences were not statistically significant between treatment groups, except that
a slightly lower proportion of patients in the placebo group enrolled in the IDNT Trial were female.
a Defined as Asian or Pacific Islander in IDNT
b Body mass index was calculated as weight (kg) divided by square of height (m)
c Mean arterial pressure was calculated as diastolic arterial pressure plus (systolic arterial pressure minus diastolic arterial pressure), divided by 3
d Pulse pressure was calculated as systolic arterial pressure minus diastolic arterial pressure
e To convert to mg/mmol, multiply by 0.113
f To convert to mol/L, multiply by 88.4, to convert to mmol/L, multiply by 0.02586
g To convert to mmol/L, multiply by 0.01129
h To convert to mmol/L, multiply by 0.6206
with microalbuminuria (with or without hypertension) subjects enrolled in the valsartan group (29.9%) com-
were randomized to receive valsartan 80 mg qd or amlo- pared with the amlodipine group (14.5%). The valsartan
dipine 5 mg qd over a 24-week period. If necessary, the and amlodipine groups experienced similar degrees of
dose of valsartan or amlodipine was doubled at week 4 blood pressure reduction.
and a diuretic (bendrofluazide) or an 	-blocker (doxa-
zoin) was added at week 8 to achieve a blood pressure
ANGIOTENSIN II-RECEPTOR-ANTAGONISTgoal of 135/85 mm Hg. The geometric mean of the
TRIALS IN PATIENTS WITH TYPE 2 DIABETESurinary albumin excretion rates from baseline to the end
AND OVERT NEPHROPATHYof the study were 58.0 to 32.3 g/min for the valsartan
As data supporting the use of ACE inhibitors in Type 2group and 55.4 to 50.7 g/min for the amlodipine group
(P  0.001). Normoalbuminuria was restored in more diabetic patients to slow the progression of renal disease
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Table 3. Primary and secondary composite endpoints and primary endpoint components
RENAAL IDNT
Irbesartan versus placebo
Losartan Placebo Risk
Composite and (N 751) (N 762) reduction Irbesartan Amlodipin Placebo Risk
components N (%) N (%) % 95% CI P value (N  579) (N  567) (N 569) reduction % 95% CI P value
DSCr, ESRD,
death 327 (43.5) 359 (47.1) 16 (2, 28) 0.02 189 (32.6) 233 (41.1) 222 (39.0) 19 (1, 33) 0.03
DSCr 162 (21.6) 198 (26.0) 25 (8, 39) 0.006 98 (16.9) 144 (25.4) 135 (23.7) 29 (8, 46) 0.009
ESRD 147 (19.6) 194 (25.5) 28 (11, 42) 0.002 82 (14.2) 104 (18.3) 101 (17.8) 17 (
11, 38) 0.19
Death 158 (21.0) 155 (20.3) 
2 (
27, 19) 0.88 87 (15.0) 83 (14.6) 93 (16.3) 6 (
27, 30) 0.69
ESRD or death 255 (34.0) 300 (39.4) 20 (5, 32) 0.01 ND ND ND ND ND ND
DSCr and ESRD 226 (30.1) 263 (34.5) 21 (5, 34) 0.01 ND ND ND ND ND ND
Secondary, cardio-
vascular com-
posite endpoint 247 (32.9) 268 (35.2) 10 (
8, 24) 0.26 138 (23.8) 128 (22.6) 144 (25.3) 9 (
14, 28) 0.40
Abbreviations are: DSCr, doubling of serum creatinine; ESRD, end-stage renal disease; ND, not determined.
are conflicting, additional studies designed to provide amlodipine (P 0.001; Fig. 1B). There was no significant
difference in the primary endpoint for placebo versusguidance toward evidence-based therapeutic approaches
for the treatment of these patients have recently been amlodipine. The relative risk of ESRD was 17% lower
for those receiving irbesartan compared with placeboconducted [19, 20]. To our knowledge these are the first
prospective, randomized trials showing that interruption and 24% lower compared with amlodipine, but these
differences did not achieve statistical significance (Fig.of the RAAS with ARBs in Type 2 diabetic subjects
with overt nephropathy delays the progression of renal 1C and Table 3). The relative risk of doubling of serum
creatinine or ESRD was similar in both the placebo anddisease. The Irbesartan Type 2 Diabetic Nephropathy
Trial (IDNT) evaluated the effect of the ARB, irbesar- amlodipine groups.
The secondary cardiovascular outcome did not showtan, on renal and cardiovascular morbidity and mortality
versus either conventional therapy or the calcium chan- statistical differences among the various arms of the
IDNT study. Those receiving irbesartan were hospital-nel blocker (CCB), amlodipine [19]. Subjects (N 1715)
were randomized to receive either irbesartan at a dose ized for heart failure at a rate 23% lower than those in
the placebo group, but once again the difference wastitrated from 75 mg to 300 mg qd; amlodipine at a dose
titrated from 2.5 mg to 10 mg qd; or placebo. Antihyper- not statistically significant. The incidence of non-fatal
myocardial infarction was 41% less in the amlodipinetensive agents other than ACE inhibitors, ARBs, and
CCBs were used as needed to achieve similar blood pres- group versus placebo.
The mean absolute rates of change in the serum creati-sure goals: a systolic blood pressure of 135 mm Hg or less,
or 10 mm Hg lower than the value at screening if that nine concentration were 0.45  0.04, 0.57  0.04, and
0.59  0.04 mg/dL/year for the irbesartan, amlodipine,value was greater than 145 mm Hg, and a diastolic pres-
sure less than 85 mm Hg. The primary composite end- and placebo arms, respectively. The mean rate of change
in creatinine clearance was 
5.5  0.36, 
6.8  0.37,point of the study was the time to a first event, namely,
doubling of baseline serum creatinine, ESRD [renal and
6.5  0.37 mL/min/1.73 m2/year for the irbesartan,
amlodipine, and placebo arms, respectively. Proteinuriatransplantation, need for dialysis, or serum creatinine
530 mol/L (6.0 mg/dL)], or death (all-cause mortal- was reduced an average of 33% in the irbesartan arm
compared with 6% and 10% in the amlodipine and pla-ity). The secondary composite outcome was time to a first
event, namely, cardiac fatality or non-fatal myocardial cebo arms, respectively. These reductions remained
throughout the study. The more favorable renal out-infarction, hospitalization for heart failure, stroke, above-
the-ankle amputation, or revascularization (cardiac, ca- comes in the irbesartan group were interpreted to be
independent of blood-pressure control.rotid, peripheral vascular). Baseline characteristics were
similar in the two treatment groups (Table 2). Results of The Reduction of Endpoints in NIDDM with the An-
giotensin II Antagonist Losartan (RENAAL) study wasthe study are summarized in Table 3. For those subjects
receiving irbesartan, the adjusted relative risk of reach- undertaken to determine whether losartan, either alone
or in combination with conventional antihypertensiveing the primary endpoint was 19% lower than placebo
(P  0.02) and 23% lower than amlodipine (P  0.006; therapy, reduces the number of patients with Type 2 diabe-
tes experiencing a doubling of serum creatinine concentra-Fig. 1A). The relative risk of doubling of serum creati-
nine concentration was 29% lower in the irbesartan tion, ESRD, or death compared to placebo-controlled
subjects [20]. Similar to IDNT, the primary endpoint ofgroup versus placebo (P  0.009) and 39% lower versus
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Fig. 1. Cumulative proportions of patients with
the primary composite endpoint (A ) and indi-
vidual components, doubling of baseline serum
creatinine concentration (B ), end-stage renal
disease (ESRD; C ). Mean follow-up time was
2.6 years.
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Fig. 2. Trough arterial blood pressure (sys-
tolic, diastolic, mean, and pulse). Abbreviations
are: P, placebo; L, losartan; CT, conven-
tional therapy. Mean follow-up time was 3.4
years (42 months).
Table 4. Baseline and concurrent antihypertensive medications used in RENAAL
At baseline During study treatment
Losartan Placebo Losartan Placebo
Therapeutic class (N 751) (N 762) (N 751) (N 762)
Calcium channel antagonist 532 (70.8) 546 (71.6) 585 (77.9) 618 (81.1)
Dihydropyridine 406 (54.1) 411 (53.9) 456 (60.7) 487 (63.9)
Diuretic 442 (58.9) 436 (57.2) 629 (83.8) 640 (84.0)
	-blocker 180 (24.0) 184 (24.1) 302 (40.2) 348 (45.7)
-blocker 137 (18.2) 140 (18.4) 256 (34.1) 280 (36.7)
Centrally acting agent 80 (10.7) 84 (11.0) 135 (18.0) 165 (21.7)
ACEI or ARB 400 (53.3) 376 (49.3) Excluded per protocol
Data are number (percent). Abbreviations are: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor antagonist.
the study was the time to a first event in the composite subjects discontinued study treatment in the placebo
group compared to the losartan group. As shown inendpoint of a doubling of serum creatinine concentra-
tion, ESRD, or death. However, the definition of ESRD Figure 2, trough systolic/diastolic blood pressure at base-
line averaged 152/82 mm Hg in the losartan group andin RENAAL was different from that in IDNT, in that
in RENAAL, ESRD was defined as the need for chronic 153/82 mm Hg in the placebo group (MAP was 105.5 vs.
106.0, P  0.38; pulse pressure (PP) was 69.4 vs. 70.8,dialysis or renal transplantation. The secondary endpoint,
cardiovascular morbidity and mortality, was a composite P 0.13). At year one, trough systolic/diastolic averaged
146/78 mm Hg and 150/80 mm Hg, at year two 143/77of myocardial infarction, stroke, first hospitalization for
heart failure or unstable angina, coronary or peripheral mm Hg and 144/77 mm Hg, and at study end 140/74
mm Hg and 142/74 mm Hg for the losartan group andrevascularization, and death from cardiovascular-related
causes. Other secondary endpoints included changes in placebo group, respectively. Corresponding values for
MAP were 100.9 versus 103.1 (P  0.001), 99.1 versusproteinuria and progression of renal disease (slope of
the reciprocal of serum creatinine concentration). 99.7 (P  0.38), and 95.9 versus 96.8 (P  0.59) for the
losartan and placebo groups, respectively. Correspond-In RENAAL 1513 subjects were randomized to re-
ceive either losartan or placebo once daily on a back- ing values for PP were 67.8 versus 69.8 (P  0.047), 66.2
versus 67.1 (P  0.37), and 66.7 versus 67.4 (P  0.77)ground of conventional antihypertensive therapy, exclud-
ing ACE inhibitors and ARBs. The dose of losartan was for the losartan and placebo groups, respectively. Table
4 lists the various classes of antihypertensive agents uti-50 or 100 mg once daily with 71% of the patients receiv-
ing 100 mg daily by the end of the study. Baseline charac- lized in the study.
Losartan treatment reduced relative risk by 16% (P teristics were similar in the two treatment groups (Table 2).
Results of the study are summarized in Table 3. More 0.024) in the primary composite endpoint of doubling of
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Fig. 3. Kaplan-Meier curves of the percentage of patients with the primary composite endpoint (A ) and individual components of the primary
composite endpoint, namely, doubling of serum creatinine (B ), end-stage renal disease (C ), and the combined endpoint of end-stage renal disease
or death (D ) in the losartan and placebo arms. Symbols are: (dashed line) placebo; (solid line) losartan. Mean follow-up time was 3.4 years (42
months). In the terminal months of the study, the losartan and placebo curves tended to converge. Such convergence is specific to one component
of the primary endpoint, namely, doubling of serum creatinine concentration (Panel 1B). This pattern, also seen previously in Type 1 diabetic
patients13, may be due in part to the higher risk profile (i.e., higher baseline serum creatinine and urine protein concentrations) of those patients
in the losartan group who remained event-free until month 40, as compared to the placebo group.
serum creatinine concentration, ESRD, or death (Fig. 25%, (P  0.002; Fig. 3B), 28% (P  0.006; Fig. 3C),
and 20% (P  0.010; Fig. 3D), respectively.3A and Table 3). The major benefit appeared to be due
to the renal components of the composite endpoint. The Changes in proteinuria, as evaluated by the urine albu-
min:creatinine ratio, were decreased by 35% in the losar-risk of doubling of serum creatinine, ESRD, and com-
bined endpoint of ESRD or death were decreased by tan arm and increased slightly in the placebo group (P 
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Fig. 5. Kaplan-Meier curve of the percentage of patients who were
hospitalized for heart failure in the losartan and placebo arms. CurvesFig. 4. Changes in proteinuria from baseline. Proteinuria was measured
represent time to first hospitalization. Subsequent hospitalizations foras the urine albumin:creatinine ratio in a first morning specimen. Abbre-
heart failure were not assessed. Abbreviations are: P, placebo; L, losar-viations are: P, placebo; L, losartan; CT, plus conventional therapy.
tan; CT, plus conventional therapy. Mean follow-up time was 3.4Mean follow-up time was 3.4 years (42 months). P  0001.
years (42 months), risk reduction was 32% and P  0.005.
0.0001, overall treatment effect between groups; Fig. 4).
treatment significantly reduces ESRD in Type 2 diabeticLosartan slowed the rate of loss of renal function by
patients at high risk for renal failure.18% relative to placebo as assessed by the reciprocal of
serum creatinine concentration (median slope 
0.056 Reprint requests to Barry Brenner, M.D., Renal Division, Department
of Medicine, Brigham and Women’s Hospital, 75 Francis St., Boston,dL/mg/year with losartan versus 
0.069 with placebo,
Massachusetts 02115-6195, USA.P 0.01). The lower value for the slope of the reciprocal
E-mail: bmbrenner@bics.bwh.harvard.edu
of serum creatinine concentration and proteinuria with
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